ALK and non-small cell lung carcinoma: The results of the exposure–response analyses of the pooled phase II studies demonstrated no significant effect of alectinib exposure on OS following administration of the recommended alectinib 600 mg BID dose in the crizotinib-resistant ALK-positive NSCLC population.